Said R. Beydoun, MD

Professor of Clinical Neurology

Richard Angus Grant, Sr., Chair in Neurology

Program Director, Clinical Neurophysiology Fellowship

Division Chief, Neuromuscular Disorders

Image of Said R. Beydoun, MD
Is this your profile? Click to edit

Overview

Said R. Beydoun, M.D., FAAN, Professor and Division Chief, Neuromuscular Medicine, at the Department of Neurology at Keck Medicine of USC, University of Southern California. He is Program Director of an ACGME-accredited Clinical Neurophysiology Fellowship, which trains three physicians each year. Dr. Beydoun advocates an integrated approach to clinical diagnosis, diagnostic testing, and treatment options for patients with neuromuscular diseases. As a principal investigator, Dr. Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of Neuromuscular Medicine include: Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Peripheral Neuropathy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), and TTR Amyloid Neuropathy. He has been published in several scientific journals on topics related to neuromuscular diseases. He is co-Editor-in-Chief of TouchReviews in Neurology. He is an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine. He is a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America. He is medical director of the Certified ALS Treatment Center of Excellence at Keck USC. He holds board certification by the American Board of Psychiatry and Neurology in Neurology, Clinical Neurophysiology, Neuromuscular Medicine, and Pain Medicine.

Publications

  • C9ORF72-associated bulbar-onset ALS in a patient with secondary progressive multiple sclerosis and conjugal ALS. Neurol Sci. 2026 Sep 26; 47(10).. View in PubMed
  • DNL343 and Disease Progression in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2026 Sep 01; 9(9):e2634809.. View in PubMed
  • Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study. Eur J Neurol. 2026 May; 33(5):e70599.. View in PubMed
  • A novel case of compound heterozygous GFPT1 congenital myasthenic syndrome with a coexisting heterozygous DYSF mutation: clinical and pathological insights. Neurol Sci. 2026 Jan 17; 47(1):170.. View in PubMed
  • Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA. 2025 Feb 17.. View in PubMed
  • CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA. 2025 Feb 17.. View in PubMed
  • Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025 04; 82(4):333-343.. View in PubMed
  • Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2459058.. View in PubMed
  • Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. Front Neurol. 2023; 14:1284444.. View in PubMed
  • Paraproteinemic Neuropathies. Continuum (Minneap Minn). 2023 10 01; 29(5):1492-1513.. View in PubMed